These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1687028)

  • 1. Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease.
    Kaise K; Kaise N; Yoshida K; Fukazawa H; Mori K; Yamamoto M; Sakurada T; Saito S; Yoshinaga K
    Endocrinol Jpn; 1991 Aug; 38(4):429-33. PubMed ID: 1687028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
    Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    Eur J Endocrinol; 2004 Oct; 151(4):467-74. PubMed ID: 15476447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
    Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
    Uy HL; Reasner CA; Samuels MH
    Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease.
    Gamstedt A; Wadman B; Karlsson A
    J Clin Endocrinol Metab; 1986 Apr; 62(4):773-7. PubMed ID: 2869050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.
    Kasagi K; Hatabu H; Tokuda Y; Iida Y; Endo K; Konishi J
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):357-66. PubMed ID: 2908031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthyroid Graves' disease without detectable thyrotropin receptor antibodies.
    Ilicki A; Gamstedt A; Karlsson FA
    J Clin Endocrinol Metab; 1992 May; 74(5):1090-4. PubMed ID: 1349025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.